Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Early Phase 1

2(40.0%)

Phase 1

2(40.0%)

Phase 3

1(20.0%)

5Total

Early Phase 1(2)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07376642Early Phase 1Recruiting

A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Role: lead

NCT07493135Early Phase 1Recruiting

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

Role: lead

NCT07103668Phase 3Recruiting

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Role: lead

NCT05472857Phase 1Recruiting

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Role: lead

NCT05946226Phase 1Unknown

A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Role: lead

All 5 trials loaded